Show Summary Details
Page of

Specific therapies for PAH 

Specific therapies for PAH
Specific therapies for PAH

Clive Handler

and Gerry Coghlan

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 20 October 2020

Supportive medical therapies in PAH 210

Advanced therapies for PAH 212

Classes of recommendations for procedures and treatments 218

Drug interactions with PAH targeted therapies 219

Combination therapy in PAH 220

Problems in conducting PAH drug trials 222

Surgical interventions 225

Anticoagulation, usually warfarin, is recommended for most patients with PAH. The rationale is based on the high frequency of thrombotic lesions in postmortem studies, the observed prothrombotic coagulation abnormalities, abnormalities in the fibrinolytic and coagulation pathways, and endothelial abnormalities, and the general prothrombotic factors—immobility and heart failure, which increase the risk of thromboembolism. Indwelling catheters for administration of prostanoids may increase the risk of local clotting and VTE, and anticoagulation is recommended for these patients....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.